Menu Search
Equities

Euroapi SA

0EAP:LSE

Euroapi SA

Actions
  • Price (EUR)2.66
  • Today's Change0.027 / 1.03%
  • Shares traded93.97k
  • 1 Year change-75.65%
  • Beta--
Data delayed at least 20 minutes, as of Apr 19 2024 18:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Euroapi SAS is a France-based company. The Company is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. It offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. The Company also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. It has production sites located in France, the United Kingdom, Germany, Italy and Hungary.

  • Revenue in EUR (TTM)1.02bn
  • Net income in EUR-189.70m
  • Incorporated2020
  • Employees3.67k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		EAPI:PAR since
announced		Transaction
value
BianoGMP GmbHDeal completed29 Aug 202329 Aug 2023Deal completed-77.63%10.82m
Data delayed at least 15 minutes, as of Apr 19 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.